Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Today, CDC's Director Rochelle P. Walensky, M.D., M.P.H., signed a decision memo allowing Novavax monovalent COVID-19 boosters for adults.

The UK Government has recommended offering a COVID-19 booster vaccination in autumn, 2024, to individuals at high risk of ...

Older adults who received the bivalent BNT162b2 vaccine were less likely to develop long COVID symptoms follow acute ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT ...

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer ...

The study showed that the sa-mRNA COVID ... the bivalent formula ARCT-2301, developed on the same platform as ARCT-154, induces superior immunogenicity over conventional bivalent mRNA vaccine ...

Arcturus and CSL shared additional data demonstrating that their bivalent vaccine ... approved/authorized the updated mRNA-based COVID-19 vaccines of Pfizer/BioNTech and Moderna MRNA that target ...

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent ...